Literature DB >> 26354090

Association of Clostridium difficile ribotype 078 with detectable toxin in human stool specimens.

Derek J Fairley1,2, James P McKenna1, Mike Stevenson3, Jeremy Weaver1, Carol Gilliland1, Alison Watt1, Peter V Coyle1,2.   

Abstract

Using a Clostridium difficile glutamate dehydrogenase (GDH) immunoassay and a sensitive C. difficile toxin A/B immunoassay, human stool specimens from patients with diarrhoea (n = 1085) were classified as either GDH positive/toxin negative, or GDH positive/toxin positive. Overall, 528/725 (73%) of the GDH-positive/toxin-negative specimens contained viable C. difficile, and 433/528 (82%) of these C. difficile isolates were PCR positive for the toxin gene pathogenicity locus. Overall, 867/1078 (80%) of the GDH-positive specimens contained viable C. difficile, and 433/725 (60%) of the GDH-positive/toxin-negative specimens contained a toxigenic C. difficile strain. The diversity of toxigenic C. difficile ribotypes isolated from toxin-negative specimens (n = 433) and toxin-positive specimens (n = 339) was significantly different (P < 0.0001). Specifically, the presence of ribotype 078 strains was very strongly associated (P < 0.0001) with detection of toxin in clinical specimens using a sensitive toxin immunoassay. Specimens positive for ribotype 078 were almost twice as likely to be toxin positive as opposed to toxin negative (risk ratio = 1.90, 95% confidence interval 1.64-2.19). In contrast, other circulating ribotypes were seen with similar frequency in specimens with and without detectable toxin. This supports the view that ribotype 078 strains may be more virulent than other common ribotypes in terms of toxin production.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26354090     DOI: 10.1099/jmm.0.000165

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  7 in total

1.  Clostridium difficile Ribotype 023 Lacks the Ability To Hydrolyze Esculin, Leading to False-Negative Results on Chromogenic Agar.

Authors:  Mairéad C Connor; Derek J Fairley; James P McKenna; Nikki J Marks; John W McGrath
Journal:  J Clin Microbiol       Date:  2016-03-09       Impact factor: 5.948

2.  Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile.

Authors:  John P Hegarty; Jacek Krzeminski; Arun K Sharma; Diana Guzman-Villanueva; Volkmar Weissig; David B Stewart
Journal:  Int J Nanomedicine       Date:  2016-08-01

3.  Evolutionary clade affects resistance of Clostridium difficile spores to Cold Atmospheric Plasma.

Authors:  Mairéad Connor; Padrig B Flynn; Derek J Fairley; Nikki Marks; Panagiotis Manesiotis; William G Graham; Brendan F Gilmore; John W McGrath
Journal:  Sci Rep       Date:  2017-02-03       Impact factor: 4.379

4.  Comparing the epidemiology of community- and hospital-associated Clostridium difficile infections in Northern Ireland, 2012-2016: a population data linkage and case-case study.

Authors:  A Maisa; G Ross; N Q Verlander; D Fairley; D T Bradley; L Patterson
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

5.  Primary care clinics can be a source of exposure to virulent Clostridium (now Clostridioides) difficile: An environmental screening study of hospitals and clinics in Dallas-Fort Worth region.

Authors:  Jerry W Simecka; Kimberly G Fulda; Mark Pulse; Joon-Hak Lee; John Vitucci; Phung Nguyen; Patricia Taylor; Frank Filipetto; Anna M Espinoza; Sushma Sharma
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

6.  A Two-Step Approach for Diagnosing Glutamate Dehydrogenase Genes by Conventional Polymerase Chain Reaction from Clostridium difficile Isolates.

Authors:  Sepideh Khodaparast; Ashraf Mohabati Mobarez; Mehdi Saberifiroozi
Journal:  Middle East J Dig Dis       Date:  2019-05-15

7.  Emergence of a non-sporulating secondary phenotype in Clostridium (Clostridioides) difficile ribotype 078 isolated from humans and animals.

Authors:  M C Connor; J W McGrath; G McMullan; N Marks; M Guelbenzu; D J Fairley
Journal:  Sci Rep       Date:  2019-09-23       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.